RMTI (Rockwell Medical Inc.) stock: $8.06, $32.5M market cap, $24.8M cash, $14.9M EV, $40.6M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Share price
$8.06
Market cap
$32.5M
Cash
$24.8M
Enterprise value
$14.9M
Balance sheet
Cash
$24.8M
Debt
$7.2M
Net cash
$17.6M
Enterprise value
$14.9M
Basic shares
4.0M shares
Fully diluted shares
5.0M shares
Fully diluted market cap
$40.6M
Cash per share
$6.20
Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.
Price history
Loading RMTI daily closes…
Loading price history…
Pipeline assets
Triferic
Stage not disclosed · ActiveModality: ferric pyrophosphate (iron replacement)
Aliases SFP (soluble ferric pyrophosphate)
Partnerships Charak, LLC: exclusive worldwide license to patents/information for Triferic (2002 agreement; Charak MSA Oct 2018 covering SFP for renal failure, IV SFP products, and TPN SFP products).
Indications
Treatment of patients with renal failure / iron disorders(Stage not disclosed)
Status note Commercial drug product within the hemodialysis concentrates business. Distribution/license agreements in China, India, South Korea, and Turkey terminated (deferred revenue fully recognized by Jun 2025). Filing excerpts do not state current approval/indication status.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.